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Background: Monocyte-derived tissue factor (TF) plays critical roles in atherothrombosis. Little is known about its post-transcriptional regulation. 
Tristetraprolin (TTP) is the most widely studied mRNA-binding protein, and binds to the 3’UTR of target mRNAs and promotes degradation. Poly(ADP-
ribose)-polymerase-14 (PARP-14), belongs to a family of ~17 proteins with a PARP domain that generates negatively charged poly(ADP-ribose) 
adducts on intracellular proteins - a post-translational modification implicated in diverse cellular functions. We have recently identified PARP-14 as a 
novel RNA-binding protein.
objectives: We sought to determine the roles for TTP and PARP-14 in regulating TF expression, and the potential role of ADP ribosylation in TF mRNA 
turnover.
meThods/resulTs: TF mRNA and protein expression were increased in TTP-/- vs TTP+/+ macrophages (p<0.05) with increased TF mRNA 
stability (t1/2=347±62min vs 82±14min,p<0.001). Similarly, TF mRNA and protein levels were increased in PARP14-/- vs. PARP-14+/+ macrophages 
(p<0.05) with increased TF mRNA stability (t1/2=181±11min vs 60±5min,p<0.001). TF mRNA, activity and protein were increased in vivo (heart, 
lung, kidney and aorta) in PARP-14-/- vs PARP-14+/+ mice (p<0.05). Intravital microscopy demonstrated a 66% reduction in median arteriolar 
occlusion time in LPS-stimulated PARP-14-/- vs PARP-14+/+ mice following ferric-chloride injury (p=0.008). RNP immunoprecipitation and RNA 
biotin pulldown assays demonstrated an interdependency for PARP-14 and TTP to form a ternary complex with TF mRNA. Inhibition of PARP activity 
reduced TF mRNA stability in PARP-14+/+ macrophages (p=0.018), but not in PARP-14-/- macrophages.
conclusions: These data define novel roles for TTP and PARP-14 in regulating TF mRNA turnover. PARP-14 functions as an accessory RNA-binding 
protein which is required for TTP to bind and degrade TF mRNA. Furthermore, inhibition of PARP-14 catalytic activity promotes TTP-mediated TF mRNA 
degradation. Thus destabilization of TF mRNA via pharmacological inhibition of PARP-14 may offer a novel therapeutic strategy in atherothrombosis 
where thrombosis is linked to TF expression.
